HUMDF (Hua Medicine) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 29, 2026)


HUMDF Hua Medicine HUMDF
46 GF Score
Price $0.34
GF Value $1.46
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Hua Medicine Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Hua Medicine's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

HUMDF vs ZTS, UTHR: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hua Medicine Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Hua Medicine's Margin of Safety % (DCF Earnings Based) falls into.


HUMDF
46GF Score
Hua Medicine HUMDF
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Hua Medicine (HUMDF) Overvalued in 2026?

Based on GuruFocus' analysis, Hua Medicine stock appears to be undervalued. The current stock price of $0.34 is trading 76.7% below its estimated GF Value™ of $1.46. GuruFocus considers Hua Medicine to be Possible Value Trap.

Key valuation signals for HUMDF:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $1.46 vs. price of $0.34 (76.7% below fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the HUMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hua Medicine Business Description

Other Exchanges 02552:Hong Kong
Address Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.
46GF Score

Get the complete analysis for HUMDF

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.34
Price
$1.46
GF Value